2023-505431-12-00CompletedPhase 1
M1774 (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients with advanced solid tumors
Source: EU CTIS (euclinicaltrials.eu) · Last updated 17 Dec 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 92 (actual)
- First submitted
- 9 Nov 2023
- Start date
- 20 Jan 2025
- Lead sponsor
- Institut Curie
- EU CT number
- 2023-505431-12-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 92
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Curie | Paris | France | Completed |
| Institut Curie | Saint-Cloud | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.